




MEWB25.001 APC

JUN 15 2003

UNITED STATES PATENT AND TRADEMARK OFFICE

— PATENT

Applicant : Lane, David Philip ) Group Art Unit 1642  
)  
Appl. No. : 09/403,440 ) I hereby certify that this correspondence and all  
Filed : January 19, 2000 ) marked attachments are being deposited with  
For : MATERIALS AND METHODS ) the United States Postal Service as first-class  
RELATING TO INHIBITING ) mail in an envelope addressed to: Assistant  
THE INTERACTION OF p53 ) Commissioner for Patents, Washington, D.C.  
AND MDM2 ) 20231, on  
Examiner : Davis, M. )  
June 11, 2001  
(Date)  
  
Ginger K. Dreger, Reg. No. 33.055

## AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In response to the Office Action mailed on March 30, 2001 (Paper No. 7) kindly amend this application as follows:

In the Specification:

Please insert the attached Sequence Listing into the specification, immediately following the claims. 

Please replace the paragraph starting at page 2, line 12 with the following new paragraph:

-- WO 96/02642 describes experiments to refine the peptide motif of p53 responsible for binding to mdm2, and shows that the motif is less extensive than disclosed in WO 93/20238. WO 96/02642 discloses that a FXaaXaaLW (SEQ ID NO: 1) motif between amino acid residues 18-23 of p53 (where Xaa is any amino acid) is sufficient to bind to mdm2. This motif can be used to screen for therapeutic compounds capable of disrupting the interaction so that the transcriptional activity of p53 in cells overexpressing mdm2 can be restored. 